Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.65 |
| ▸ | MEN1 | O00255 | 1/20 | 0.65 |
| ▸ | HPGD | P15428 | 12/20 | 0.61 |
| ▸ | SMN1; SMN2 | Q16637 | 9/20 | 0.61 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.61 |
| ▸ | TSHR | P16473 | 2/20 | 0.61 |
| ▸ | NPC1 | O15118 | 1/20 | 0.58 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.58 |
| ▸ | LMNA | P02545 | 4/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.56 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.56 |
| ▸ | MAPT | P10636 | 2/20 | 0.55 |
| ▸ | POLB | P06746 | 1/20 | 0.55 |
| ▸ | RAB9A | P51151 | 1/20 | 0.55 |
| ▸ | GAA | P10253 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15947382 | 0.83 | KMT2A (0.77) | KMT2AMEN1HPGDSMN1; SMN2L3MBTL1 | |
| SCHEMBL4911660 | 0.81 | SMN1; SMN2 (0.54) | KMT2AMEN1HPGDSMN1; SMN2L3MBTL1 | |
| SCHEMBL4911658 | 0.81 | SMN1; SMN2 (0.54) | KMT2AMEN1HPGDSMN1; SMN2L3MBTL1 | |
| SCHEMBL25961852 | 0.81 | SMN1; SMN2 (0.54) | KMT2AMEN1HPGDSMN1; SMN2L3MBTL1 | |
| SCHEMBL14853589 | 0.81 | KMT2A (0.73) | KMT2AMEN1HPGDSMN1; SMN2L3MBTL1 | |
| SCHEMBL8404658 | 0.80 | KMT2A (0.81) | KMT2AMEN1HPGDSMN1; SMN2L3MBTL1 | |
| SCHEMBL3408099 | 0.80 | KMT2A (0.81) | KMT2AMEN1HPGDSMN1; SMN2L3MBTL1 | |
| Bromide SCHEMBL11867443 | 0.80 | KMT2A (0.71) | KMT2AMEN1HPGDSMN1; SMN2L3MBTL1 | |
| SCHEMBL7447564 | 0.79 | KMT2A (0.83) | KMT2AMEN1HPGDSMN1; SMN2L3MBTL1 | |
| SCHEMBL8404659 | 0.78 | KMT2A (0.81) | KMT2AMEN1HPGDSMN1; SMN2L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9328085-B2 | Heterocyclic compounds and expansion agents for hematopoietic stem cells | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2016-05-03 | — | — | US | disclosed |
| US-20130245255-A1 | HETEROCYCLIC COMPOUNDS AND EXPANSION AGENTS FOR HEMATOPOIETIC STEM CELLS | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2013-09-19 | — | — | US | disclosed |
| US-20120128640-A1 | HETEROCYCLIC COMPOUNDS AND EXPANSION AGENTS FOR HEMATOPOIETIC STEM CELLS | NISSAN CHEMICAL INDUSTRIES LTD. (JP) | 2012-05-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130245255-A1 | HETEROCYCLIC COMPOUNDS AND EXPANSION AGENTS FOR HEMATOPOIETIC STEM CELLS | HCLS1, RUNX1, RCC1 | KMT2A 1024/4885MEN1 1209/4885HPGD 750/4885 |
| US-20120128640-A1 | HETEROCYCLIC COMPOUNDS AND EXPANSION AGENTS FOR HEMATOPOIETIC STEM CELLS | HCLS1, RUNX1, RCC1 | KMT2A 1024/4885MEN1 1209/4885HPGD 750/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.